Search

Advocacy priorities

The European Union works on countless pieces of legislation and policies that affect the health ecosystem. Some are relevant to most medical disciplines, including hematology—such as the legislation on health data or pharmaceuticals.

Read more

Faculty information

We are honored that you have agreed to be part of the faculty for the EHA-HKSH Hematology Tutorial on Lymphoid Malignancies, to be held on April 5-6, 2025 in Hong Kong.

Read more

Health Technology Assessment (HTA)

Every European citizen should have access to the best quality medical care at the best possible price. Pan-European cooperation on health technology assessments (HTA) is essential for such aspirations.

Read more

Sickle Cell Disease: From Research to Clinical Management

Elevate your expertise and impact patient care by joining the EHA's pilot preceptorship on Sickle Cell Disease, designed for early-career hematology specialists, clinicians, lab technicians, and pathologists.

Read more

EHA2022 Gallery

Thank you to the Faculty, delegates, and industry partners for contributing to the EHA2022 Hybrid Congress.

Read more

EHA2024 gallery

Thank you to the esteemed faculty, delegates, and industry partners for their valuable contributions to the EHA2024 Hybrid Congress, which took place in Madrid and online from June 13–16.

Read more

Code of Conduct

The guidelines below govern the publication of, and commentary on the EHA Hematology Hub. Please read through them before participating. 1. Abide by the rules that normally apply.

Read more

Improved survival for adult Acute Lymphoblastic Leukemia (ALL) patients

Historical survival for patients 18-45 years with ALL is approximately 40 %. However the event free survival for ALL patients 18-45 years has improved to 73% following implementation of the NOPHO ALL2008 protocol in July 2008.

Read more